SAMHD1 and HIV-1 infection: Vpx degrades SAMHD1, overcoming the block to HIV-1 infection of resting T cells and primary monocytes [33, 34, 42, 43] allowing us to test how well the drug blocks infection and to investigate its antiviral mechanism.